Your browser doesn't support javascript.
loading
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.
Cornely, Oliver A; Cisneros, José M; Torre-Cisneros, Julian; Rodríguez-Hernández, María Jesús; Tallón-Aguilar, Luis; Calbo, Esther; Horcajada, Juan P; Queckenberg, Christian; Zettelmeyer, Ulrike; Arenz, Dorothee; Rosso-Fernández, Clara M; Jiménez-Jorge, Silvia; Turner, Guy; Raber, Susan; O'Brien, Seamus; Luckey, Alison.
Afiliação
  • Cornely OA; University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Clinical Trials Centre Cologne (CTC Cologne), Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, German Centre for Infection Research (DZIF) partner
  • Cisneros JM; Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Torre-Cisneros J; Reina Sofia University Hospital-IMIBIC-UCO, Córdoba, Spain.
  • Rodríguez-Hernández MJ; Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Tallón-Aguilar L; Hospital Universitario Virgen Macarena, Seville, Spain.
  • Calbo E; Hospital Universitario Mútua de Tarrasa and Universitat Internacional de Catalunya, Barcelona, Spain.
  • Horcajada JP; Hospital del Mar, IMIM, UAB, Barcelona, Spain.
  • Queckenberg C; University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Clinical Trials Centre Cologne (CTC Cologne), Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, German Centre for Infection Research (DZIF) partner
  • Zettelmeyer U; University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Clinical Trials Centre Cologne (CTC Cologne), Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, German Centre for Infection Research (DZIF) partner
  • Arenz D; University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Clinical Trials Centre Cologne (CTC Cologne), Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, German Centre for Infection Research (DZIF) partner
  • Rosso-Fernández CM; Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Jiménez-Jorge S; Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Turner G; Pfizer, New York, NY, USA.
  • Raber S; Pfizer, La Jolla, CA, USA.
  • O'Brien S; Pfizer, New York, NY, USA.
  • Luckey A; Pfizer, New York, NY, USA.
J Antimicrob Chemother ; 75(3): 618-627, 2020 03 01.
Article em En | MEDLINE | ID: mdl-31828337
ABSTRACT

OBJECTIVES:

To investigate pharmacokinetics (PK) and safety (primary objectives) and efficacy (secondary objective) of the investigational monobactam/ß-lactamase inhibitor combination aztreonam/avibactam in patients with complicated intra-abdominal infection (cIAI).

METHODS:

This Phase 2a open-label, multicentre study (NCT02655419; EudraCT 2015-002726-39) enrolled adults with cIAI into sequential cohorts for 5-14 days treatment. Cohort 1 patients received an aztreonam/avibactam loading dose of 500/137 mg (30 min infusion), followed by maintenance doses of 1500/410 mg (3 h infusions) q6h; Cohort 2 received 500/167 mg (30 min infusion), followed by 1500/500 mg (3 h infusions) q6h. Cohort 3 was an extension of exposure at the higher dose regimen. Doses were adjusted for creatinine clearance of 31-50 mL/min (Cohorts 2 + 3). All patients received IV metronidazole 500 mg q8h. PK, safety and efficacy were assessed.

RESULTS:

Thirty-four patients (Cohort 1, n = 16; Cohorts 2 + 3, n = 18) comprised the modified ITT (MITT) population. Mean exposures of aztreonam and avibactam in Cohorts 2 + 3 were consistent with those predicted to achieve joint PK/pharmacodynamic target attainment in >90% patients. Adverse events (AEs) were similar between cohorts. The most common AEs were hepatic enzyme increases [n = 9 (26.5%)] and diarrhoea [n = 5 (14.7%)]. Clinical cure rates at the test-of-cure visit overall were 20/34 (58.8%) (MITT) and 14/23 (60.9%) (microbiological-MITT population).

CONCLUSIONS:

Observed AEs were consistent with the known safety profile of aztreonam monotherapy, with no new safety concerns identified. These data support selection of the aztreonam/avibactam 500/167 mg (30 min infusion) loading dose and 1500/500 mg (3 h infusions) maintenance dose q6h regimen, in patients with creatinine clearance >50 mL/min, for the Phase 3 development programme.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aztreonam / Infecções Intra-Abdominais Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aztreonam / Infecções Intra-Abdominais Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article